JP2016539164A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539164A5 JP2016539164A5 JP2016536659A JP2016536659A JP2016539164A5 JP 2016539164 A5 JP2016539164 A5 JP 2016539164A5 JP 2016536659 A JP2016536659 A JP 2016536659A JP 2016536659 A JP2016536659 A JP 2016536659A JP 2016539164 A5 JP2016539164 A5 JP 2016539164A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutically acceptable
- acceptable salt
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 12
- 238000013268 sustained release Methods 0.000 claims 11
- 239000012730 sustained-release form Substances 0.000 claims 11
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 8
- 229960003086 naltrexone Drugs 0.000 claims 8
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 7
- 229960001058 bupropion Drugs 0.000 claims 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims 6
- 208000006011 Stroke Diseases 0.000 claims 6
- 230000002526 effect on cardiovascular system Effects 0.000 claims 4
- 230000002411 adverse Effects 0.000 claims 3
- 230000007211 cardiovascular event Effects 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 230000000250 revascularization Effects 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 206010002388 Angina unstable Diseases 0.000 claims 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000007814 Unstable Angina Diseases 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 2
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010014486 Elevated triglycerides Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000004301 Sinus Arrhythmia Diseases 0.000 claims 1
- 206010065341 Ventricular tachyarrhythmia Diseases 0.000 claims 1
- 210000003423 ankle Anatomy 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 210000003141 lower extremity Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 208000003663 ventricular fibrillation Diseases 0.000 claims 1
- 206010047302 ventricular tachycardia Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913216P | 2013-12-06 | 2013-12-06 | |
| US61/913,216 | 2013-12-06 | ||
| US201361914938P | 2013-12-11 | 2013-12-11 | |
| US61/914,938 | 2013-12-11 | ||
| US201461984580P | 2014-04-25 | 2014-04-25 | |
| US61/984,580 | 2014-04-25 | ||
| US14/322,810 US8969371B1 (en) | 2013-12-06 | 2014-07-02 | Compositions and methods for weight loss in at risk patient populations |
| US14/322,810 | 2014-07-02 | ||
| PCT/US2014/068527 WO2015085044A1 (en) | 2013-12-06 | 2014-12-04 | Compositions and methods for reducing major adverse cardiovascular events |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019220444A Division JP7204634B2 (ja) | 2013-12-06 | 2019-12-05 | 主要有害心血管事象を低減するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539164A JP2016539164A (ja) | 2016-12-15 |
| JP2016539164A5 true JP2016539164A5 (OSRAM) | 2018-01-18 |
| JP6665094B2 JP6665094B2 (ja) | 2020-03-13 |
Family
ID=52575014
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536659A Active JP6665094B2 (ja) | 2013-12-06 | 2014-12-04 | 主要有害心血管事象を低減するための組成物及び方法 |
| JP2019220444A Active JP7204634B2 (ja) | 2013-12-06 | 2019-12-05 | 主要有害心血管事象を低減するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019220444A Active JP7204634B2 (ja) | 2013-12-06 | 2019-12-05 | 主要有害心血管事象を低減するための組成物及び方法 |
Country Status (33)
| Country | Link |
|---|---|
| US (9) | US8969371B1 (OSRAM) |
| EP (2) | EP3076971B1 (OSRAM) |
| JP (2) | JP6665094B2 (OSRAM) |
| KR (3) | KR20220165791A (OSRAM) |
| CN (3) | CN117159547A (OSRAM) |
| AU (1) | AU2014360492A1 (OSRAM) |
| BR (1) | BR112016012755A2 (OSRAM) |
| CA (1) | CA2932127C (OSRAM) |
| CL (1) | CL2016001362A1 (OSRAM) |
| CR (1) | CR20160313A (OSRAM) |
| CY (1) | CY1125114T1 (OSRAM) |
| DK (1) | DK3076971T3 (OSRAM) |
| EA (1) | EA201690964A1 (OSRAM) |
| EC (1) | ECSP16057765A (OSRAM) |
| ES (1) | ES2903391T3 (OSRAM) |
| HR (1) | HRP20220058T1 (OSRAM) |
| HU (1) | HUE057551T2 (OSRAM) |
| IL (3) | IL300870A (OSRAM) |
| JO (1) | JOP20140344B1 (OSRAM) |
| LT (1) | LT3076971T (OSRAM) |
| MX (2) | MX389742B (OSRAM) |
| PE (1) | PE20161034A1 (OSRAM) |
| PL (1) | PL3076971T3 (OSRAM) |
| PT (1) | PT3076971T (OSRAM) |
| RS (1) | RS62846B1 (OSRAM) |
| RU (1) | RU2711638C2 (OSRAM) |
| SG (1) | SG10201808055QA (OSRAM) |
| SI (1) | SI3076971T1 (OSRAM) |
| TN (1) | TN2016000231A1 (OSRAM) |
| TW (1) | TWI661826B (OSRAM) |
| UY (1) | UY35864A (OSRAM) |
| WO (1) | WO2015085044A1 (OSRAM) |
| ZA (1) | ZA201603831B (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05011557A (es) | 2003-04-29 | 2006-03-09 | Orexigen Therapeutics Inc | Composiciones para afectar perdida de peso. |
| JP5180092B2 (ja) | 2005-11-22 | 2013-04-10 | オレキシジェン・セラピューティクス・インコーポレーテッド | インスリン感受性を増すための組成物および方法 |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| MX343867B (es) | 2006-11-09 | 2016-11-25 | Orexigen Therapeutics Inc | Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso. |
| MX2010012909A (es) | 2008-05-30 | 2011-02-25 | Orexigen Therapeutics Inc | Metodos para tratamiento de condiciones de grasa visceral. |
| EP2523557B1 (en) | 2010-01-11 | 2019-09-25 | Nalpropion Pharmaceuticals, Inc. | Methods of providing weight loss therapy in patients with major depression |
| PL4104824T3 (pl) * | 2012-06-06 | 2025-11-12 | Nalpropion Pharmaceuticals Llc | Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
| JP6731540B2 (ja) * | 2016-08-11 | 2020-07-29 | 華為技術有限公司Ｈｕａｗｅｉ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｃｏ．，Ｌｔｄ． | 免許不要帯域に基づく無線通信方法、基地局、及び端末デバイス |
| US20250332152A1 (en) * | 2021-12-09 | 2025-10-30 | Incarda Therapeutics, Inc. | Inhaled therapy for cardiac arrhythmia |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217353A (en) | 1978-05-19 | 1980-08-12 | E. I. Du Pont De Nemours And Company | Method for inducing anorexia |
| IL58649A (en) | 1978-11-10 | 1982-04-30 | Beecham Group Ltd | Pharmaceutical dispensing container |
| JPS59500418A (ja) | 1982-03-16 | 1984-03-15 | ザ ロツクフエラ− ユニバ−シテイ | 胃腸能動作用障害を回復する方法 |
| GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| PH23901A (en) | 1987-05-04 | 1989-12-18 | Lilly Co Eli | Treatment of diabetes using fluoxetine |
| US5486362A (en) | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
| US5403595A (en) | 1991-05-07 | 1995-04-04 | Dynagen, Inc. | Controlled, sustained release delivery system for smoking cessation |
| DE4136215A1 (de) | 1991-11-02 | 1993-05-06 | Ferring Arzneimittel Gmbh, 2300 Kiel, De | Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie |
| US5512593A (en) | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
| EP0782445B1 (en) | 1994-09-19 | 2002-03-13 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
| US5627187A (en) | 1995-04-12 | 1997-05-06 | Katz; Bruce E. | 5-FU for treating actinic kerotoses |
| GB9517062D0 (en) | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
| US5716976A (en) | 1996-03-13 | 1998-02-10 | Bernstein; Richard K. | Method of treatment for carbohydrate addiction |
| EP0795327A1 (en) * | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin |
| EP0828489A4 (en) | 1996-03-13 | 2001-04-04 | Univ Yale | Smoking cessation treatments using naltrexone and related compounds |
| PT934069E (pt) | 1996-05-07 | 2007-02-28 | Pliva Istrazivanje I Razvoj D | Método e composição para o tratamento de perturbações do metabolismo dos lípidos e glucose |
| NZ333586A (en) | 1996-06-28 | 2000-05-26 | Ortho Mcneil Pharm Inc | Anticonvulsant sulfamate derivatives, preferably topiramate, useful in treating obesity |
| US5878750A (en) | 1996-11-14 | 1999-03-09 | Clemens; Anton H. | Method of treating the syndrome of coronary heart disease risk factors in humans |
| JP2001518520A (ja) | 1997-10-03 | 2001-10-16 | キャリー メディカル コーポレイション | ニコチンレセプターアンタゴニストおよび抗抑うつ薬または抗不安薬を含有するニコチン嗜癖を治療する組成物 |
| US6262049B1 (en) | 1997-10-28 | 2001-07-17 | Schering Corporation | Method of reducing nicotine and tobacco craving in mammals |
| US6110973A (en) | 1998-01-29 | 2000-08-29 | Sepracor | Methods for treating obesity and weight gain using optically pure (-)-bupropion |
| US6048322A (en) | 1998-04-15 | 2000-04-11 | Kushida; Clete | Morphometric measurement tool |
| US6210716B1 (en) | 1999-02-26 | 2001-04-03 | Andrx Pharmaceuticals, Inc. | Controlled release bupropion formulation |
| US6589553B2 (en) | 2001-02-08 | 2003-07-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral dosage form |
| NZ514811A (en) | 1999-04-08 | 2005-01-28 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful in reducing blood glucose levels |
| US6071918A (en) | 1999-07-21 | 2000-06-06 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
| JP2003509349A (ja) | 1999-09-15 | 2003-03-11 | エラン ファーマシューティカルズ，インコーポレイテッド | ヘテロアリールメタンスルホンアミドを使用するニューロパシー性疼痛を処置するための方法。 |
| US6403657B1 (en) | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
| AR031682A1 (es) | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
| GB0001449D0 (en) | 2000-01-21 | 2000-03-08 | Cortendo Ab | Compositions |
| US20020055512A1 (en) | 2000-01-21 | 2002-05-09 | Cortendo Ab. | Compositions for delivery of a cortisol antagonist |
| CN1406129A (zh) | 2000-01-22 | 2003-03-26 | 艾伯特·舒尔曼 | 用于治疗物质滥用的方法 |
| WO2001052851A1 (en) | 2000-01-22 | 2001-07-26 | Albert Shulman | Methods for the treatment of substance abuse |
| DE60138706D1 (de) | 2000-02-08 | 2009-06-25 | Euro Celtique Sa | Missbrauchssichere orale opioid-agonist zubereitungen |
| US6306436B1 (en) | 2000-04-28 | 2001-10-23 | Teva Pharmaceuticals Usa, Inc. | Stabilized, acid-free formulation for sustained release of bupropion hydrochloride |
| US6528520B2 (en) | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| DK1326630T3 (da) | 2000-09-18 | 2008-09-15 | Sanos Bioscience As | Anvendelse af GLP-2-peptider |
| AU2002314968B2 (en) | 2001-06-08 | 2006-12-07 | Endo Pharmaceuticals, Inc. | Controlled release dosage forms using acrylic polymer, and process for making the same |
| US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
| DE20220910U1 (de) | 2001-08-06 | 2004-08-05 | Euro-Celtique S.A. | Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden |
| DK1414451T3 (da) | 2001-08-06 | 2009-08-10 | Euro Celtique Sa | Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist |
| US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
| US20030087896A1 (en) | 2001-08-09 | 2003-05-08 | Hillel Glover | Treatment of refractory depression with an opiate antagonist and an antidepressant |
| US20040102440A1 (en) | 2002-07-01 | 2004-05-27 | Wong Erik Ho Fong | Method of promoting smoking cessation |
| US20040029941A1 (en) | 2002-05-06 | 2004-02-12 | Jennings Julianne E. | Zonisamide use in obesity and eating disorders |
| EP2301537A1 (en) | 2002-05-17 | 2011-03-30 | Duke University | Zonisamide for the treatment of obesity |
| CN100411618C (zh) | 2002-05-17 | 2008-08-20 | 迪欧加药品公司 | 有效的选择性阿片受体调制剂化合物的用途 |
| US20040005368A1 (en) | 2002-07-01 | 2004-01-08 | Morris Mann | Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite |
| US6972291B2 (en) | 2002-07-02 | 2005-12-06 | Bernstein Richard K | Method for reducing food intake |
| US7086532B2 (en) | 2003-07-16 | 2006-08-08 | Allergan, Inc. | Titration/compliance pack with increasing doses |
| AU2003283958A1 (en) | 2002-09-13 | 2004-04-30 | Elan Pharmaceuticals, Inc. | Method of treating tremors |
| US20040192715A1 (en) | 2003-02-05 | 2004-09-30 | Mark Chasin | Methods of administering opioid antagonists and compositions thereof |
| US20040204472A1 (en) | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
| US20050038062A1 (en) | 2003-04-14 | 2005-02-17 | Burns Lindsay H. | Methods and materials for the treatment of pain comprising opioid antagonists |
| MXPA05011557A (es) | 2003-04-29 | 2006-03-09 | Orexigen Therapeutics Inc | Composiciones para afectar perdida de peso. |
| CN1791430A (zh) | 2003-05-16 | 2006-06-21 | 辉瑞产品公司 | 非典型抗精神病药物和gaba调节剂、抗惊厥药物或苯并二氮杂䓬类的治疗性组合 |
| US20070099884A1 (en) | 2003-06-06 | 2007-05-03 | Erondu Ngozi E | Combination therapy for the treatment of diabetes |
| CA2539027C (en) | 2003-09-25 | 2010-02-23 | Euro-Celtique S.A. | Pharmaceutical combinations of hydrocodone and naltrexone |
| US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
| US20070149451A1 (en) | 2003-11-17 | 2007-06-28 | Holmes David G | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent |
| JP2007517901A (ja) | 2004-01-13 | 2007-07-05 | デューク・ユニバーシティー | 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物 |
| US20050245541A1 (en) | 2004-03-19 | 2005-11-03 | Elliot Ehrich | Methods for treating alcoholism |
| CA2565154A1 (en) | 2004-05-03 | 2005-11-24 | Duke University | Compositions for affecting weight loss |
| US20050250838A1 (en) | 2004-05-04 | 2005-11-10 | Challapalli Prasad V | Formulation for sustained delivery |
| BRPI0514060A (pt) | 2004-08-03 | 2008-05-27 | Orexigen Therapeutics Inc | combinação de bupropion e um segundo composto para acarretar a perda de peso |
| WO2007047351A2 (en) | 2005-10-13 | 2007-04-26 | Orexigen Therapeutics, Inc. | Methods for treating hypertension in overweight and obese individuals |
| US20070099947A1 (en) | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
| JP5180092B2 (ja) | 2005-11-22 | 2013-04-10 | オレキシジェン・セラピューティクス・インコーポレーテッド | インスリン感受性を増すための組成物および方法 |
| WO2007089318A2 (en) | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| US20070179168A1 (en) | 2005-11-28 | 2007-08-02 | Orexigen Therapeutics, Inc. | Methods of treating anxiety disorders |
| EP1813276A1 (en) | 2006-01-27 | 2007-08-01 | Euro-Celtique S.A. | Tamper resistant dosage forms |
| ES2749800T3 (es) | 2006-06-05 | 2020-03-23 | Nalpropion Pharmaceuticals Llc | Formulación de liberación sostenida de naltrexona |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| MX2008016372A (es) | 2006-06-19 | 2009-05-28 | Alpharma Inc | Composiciones farmaceuticas. |
| WO2008011150A1 (en) | 2006-07-20 | 2008-01-24 | Somaxon Pharmaceuticals, Inc. | Methods of improving the pharmacokinetics of doxepin |
| US8682445B2 (en) | 2006-07-28 | 2014-03-25 | Cyberonics, Inc. | Patient management system for treating depression using an implantable medical device |
| MX343867B (es) | 2006-11-09 | 2016-11-25 | Orexigen Therapeutics Inc | Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso. |
| KR101654176B1 (ko) | 2006-11-09 | 2016-09-09 | 오렉시젠 세러퓨틱스 인크. | 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형 |
| GB2447949B (en) | 2007-03-29 | 2010-03-31 | Renasci Consultancy Ltd | A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission |
| US8318813B2 (en) | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
| MX2010012909A (es) | 2008-05-30 | 2011-02-25 | Orexigen Therapeutics Inc | Metodos para tratamiento de condiciones de grasa visceral. |
| EP2523557B1 (en) | 2010-01-11 | 2019-09-25 | Nalpropion Pharmaceuticals, Inc. | Methods of providing weight loss therapy in patients with major depression |
| SMT201700537T1 (it) | 2010-12-03 | 2018-01-11 | Orexigen Therapeutics Inc | Metodi per ridurre l'alimentazione incontrollata o compulsiva |
| PL4104824T3 (pl) | 2012-06-06 | 2025-11-12 | Nalpropion Pharmaceuticals Llc | Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
-
2014
- 2014-07-02 US US14/322,810 patent/US8969371B1/en active Active
- 2014-12-03 JO JOP/2014/0344A patent/JOP20140344B1/ar active
- 2014-12-04 RS RS20220039A patent/RS62846B1/sr unknown
- 2014-12-04 KR KR1020227041333A patent/KR20220165791A/ko not_active Ceased
- 2014-12-04 RU RU2016122483A patent/RU2711638C2/ru active
- 2014-12-04 EP EP14867191.0A patent/EP3076971B1/en active Active
- 2014-12-04 SI SI201431935T patent/SI3076971T1/sl unknown
- 2014-12-04 CN CN202310405573.1A patent/CN117159547A/zh active Pending
- 2014-12-04 EP EP21202875.7A patent/EP4005571A1/en active Pending
- 2014-12-04 UY UY0001035864A patent/UY35864A/es not_active Application Discontinuation
- 2014-12-04 TN TN2016000231A patent/TN2016000231A1/en unknown
- 2014-12-04 SG SG10201808055QA patent/SG10201808055QA/en unknown
- 2014-12-04 CN CN202111066895.5A patent/CN114404419A/zh active Pending
- 2014-12-04 KR KR1020237036479A patent/KR20230152800A/ko active Pending
- 2014-12-04 KR KR1020167017977A patent/KR102472432B1/ko active Active
- 2014-12-04 EA EA201690964A patent/EA201690964A1/ru unknown
- 2014-12-04 DK DK14867191.0T patent/DK3076971T3/da active
- 2014-12-04 LT LTEPPCT/US2014/068527T patent/LT3076971T/lt unknown
- 2014-12-04 BR BR112016012755A patent/BR112016012755A2/pt not_active Application Discontinuation
- 2014-12-04 CA CA2932127A patent/CA2932127C/en active Active
- 2014-12-04 MX MX2016007231A patent/MX389742B/es unknown
- 2014-12-04 CN CN201480072729.8A patent/CN105899210A/zh active Pending
- 2014-12-04 AU AU2014360492A patent/AU2014360492A1/en not_active Abandoned
- 2014-12-04 CR CR20160313A patent/CR20160313A/es unknown
- 2014-12-04 PE PE2016000724A patent/PE20161034A1/es unknown
- 2014-12-04 HU HUE14867191A patent/HUE057551T2/hu unknown
- 2014-12-04 PT PT148671910T patent/PT3076971T/pt unknown
- 2014-12-04 ES ES14867191T patent/ES2903391T3/es active Active
- 2014-12-04 HR HRP20220058TT patent/HRP20220058T1/hr unknown
- 2014-12-04 JP JP2016536659A patent/JP6665094B2/ja active Active
- 2014-12-04 IL IL300870A patent/IL300870A/en unknown
- 2014-12-04 US US15/101,878 patent/US10231962B2/en active Active
- 2014-12-04 PL PL14867191T patent/PL3076971T3/pl unknown
- 2014-12-04 WO PCT/US2014/068527 patent/WO2015085044A1/en not_active Ceased
- 2014-12-05 TW TW103142498A patent/TWI661826B/zh active
-
2015
- 2015-03-02 US US14/635,518 patent/US9119850B2/en active Active
- 2015-08-28 US US14/839,792 patent/US9801875B2/en active Active
-
2016
- 2016-05-30 IL IL245919A patent/IL245919A0/en unknown
- 2016-06-02 MX MX2022001251A patent/MX2022001251A/es unknown
- 2016-06-03 CL CL2016001362A patent/CL2016001362A1/es unknown
- 2016-06-06 ZA ZA2016/03831A patent/ZA201603831B/en unknown
- 2016-07-04 EC ECIEPI201657765A patent/ECSP16057765A/es unknown
-
2017
- 2017-10-05 US US15/725,830 patent/US10231964B2/en active Active
-
2019
- 2019-03-18 US US16/356,657 patent/US10828294B2/en active Active
- 2019-03-18 US US16/356,663 patent/US10835527B2/en active Active
- 2019-12-05 JP JP2019220444A patent/JP7204634B2/ja active Active
-
2020
- 2020-11-16 US US17/099,316 patent/US11998542B2/en active Active
-
2021
- 2021-04-07 IL IL282117A patent/IL282117A/en unknown
-
2022
- 2022-01-19 CY CY20221100048T patent/CY1125114T1/el unknown
-
2024
- 2024-06-03 US US18/731,965 patent/US20250144089A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539164A5 (OSRAM) | ||
| HRP20220058T1 (hr) | Sastavi i metode za smanjenje velikih neželjenih kardiovaskularnih događaja | |
| JP2022062151A5 (OSRAM) | ||
| Stiell et al. | A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm | |
| Conde et al. | Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation | |
| RU2011148362A (ru) | Стабильные фармацевтические композиции и способы их применения | |
| EP2300001A1 (en) | Dronedarone for the prevention of permanent atrial fibrillation | |
| JP2019206562A5 (OSRAM) | ||
| Onk et al. | Is the preoperative administration of amiodarone or metoprolol more effective in reducing atrial fibrillation: after coronary bypass surgery? | |
| HRP20250931T1 (hr) | Pripravak za upotrebu u postupku liječenja prekomjerne težine i pretilosti kod pacijenata s visokim kardiovaskularnim rizikom | |
| Crijns | Rate versus rhythm control in patients with atrial fibrillation: what the trials really say | |
| Quah et al. | The management of the older adult patient with anomalous left coronary artery from the pulmonary artery syndrome: a presentation of two cases and review of the literature | |
| JP2019514925A5 (OSRAM) | ||
| Takahiro et al. | Accidental hypothermia-induced electrical storm successfully treated with isoproterenol | |
| Camm et al. | Medical treatment of atrial fibrillation | |
| Vora et al. | Control of heart rate versus rhythm in rheumatic atrial fibrillation: a randomized study | |
| Demangone | ECG manifestations: noncoronary heart disease | |
| JP2020523408A5 (OSRAM) | ||
| Selvaraj et al. | Effect of single intraoperative dose of amiodarone in patients with rheumatic valvular heart disease and atrial fibrillation undergoing valve replacement surgery | |
| Duggan et al. | Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation | |
| Efthimiadis et al. | Hypertrophic cardiomyopathy associated with an anomalous origin of right coronary artery: case report and review of the literature | |
| Breithardt et al. | Acute effects of resynchronisation treatment on functional mitral regurgitation in dilated cardiomyopathy | |
| Yavuz et al. | Role of endogenous adenosine in atrial fibrillation after coronary artery bypass graft | |
| Nagra et al. | Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale | |
| EP2386300A1 (en) | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality in patients having a first recurrence of atrial fibrillation or atrial flutter |